Multi-Institutional Survey of Medical Treatment for Late-Onset Hypogonadism in Japan

Am J Mens Health. 2017 Mar;11(2):376-379. doi: 10.1177/1557988316681668. Epub 2016 Dec 5.

Abstract

The adequate criteria for late-onset hypogonadism (LOH) diagnosis, including serum testosterone levels, type (total or free testosterone) and duration of androgen replacement therapy, and evaluations of treatment effectiveness remain controversial. To evaluate the current status of medical treatment for LOH in Japan, the first nationwide survey were performed. A total of 35 questionnaires answered by urologists in high-volume facilities were analyzed. The median numbers of patients with hypogonadism-related symptoms per month were 10. Aging Male Symptom Score, International Index of Erectile Function, and International Prostate Symptom Score questionnaires were widely used for questionnaires. The diagnostic criteria for LOH varied. Among the patients who presented with hypogonadism-related symptoms, the mean proportion of patients undergoing treatment for LOH was 62.3%. In Japan, LOH was treated not only with testosterone enanthate injections or testosterone ointment but also with Kampo medicine. In many facilities, LOH treatment effectiveness was assessed after a 3-month period. Efficacy was assessed in different ways. Treatment effectiveness rate ranged from 30% to 80%. The duration of LOH treatment was not fixed and was established individually by both the patient and treating physician. This study showed that the real clinical practices for LOH are very diverse, and a general consensus is needed.

Keywords: Aging Male Symptom Score; androgen replacement therapy; late-onset hypogonadism.

MeSH terms

  • Asian People*
  • Hormone Replacement Therapy*
  • Humans
  • Hypogonadism / therapy*
  • Japan
  • Late Onset Disorders / therapy
  • Male
  • Severity of Illness Index
  • Testosterone*

Substances

  • Testosterone